These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16189845)

  • 1. Drug for "off" episodes of Parkinson's--effective but limited.
    Mayo Clin Health Lett; 2005 Jul; 23(7):4. PubMed ID: 16189845
    [No Abstract]   [Full Text] [Related]  

  • 2. New drug helps Parkinson's "off" periods.
    Health News; 2004 Jul; 10(7):2. PubMed ID: 15239150
    [No Abstract]   [Full Text] [Related]  

  • 3. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment for people with Parkinson's.
    FDA Consum; 2004; 38(4):5. PubMed ID: 15346564
    [No Abstract]   [Full Text] [Related]  

  • 6. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
    Obering CD; Chen JJ; Swope DM
    Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug treatments and motor complications in advanced stage Parkinson's disease ].
    Marion MH
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():160-4. PubMed ID: 10916047
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
    van Laar T; Postma AG; Drent M
    Parkinsonism Relat Disord; 2010 Jan; 16(1):71-2. PubMed ID: 19524477
    [No Abstract]   [Full Text] [Related]  

  • 9. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract]   [Full Text] [Related]  

  • 11. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
    Pahwa R; Koller WC; Trosch RM; Sherry JH;
    J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of apomorphine in Parkinson s disease].
    Giménez-Roldán S; García- Muñozguren S
    Rev Neurol; 2002 Oct 1-15; 35(7):668-74. PubMed ID: 12389155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
    Pot C; Oppliger R; Castillo V; Coeytaux A; Hauser C; Burkhard PR
    Neurology; 2005 Jan; 64(2):392-3. PubMed ID: 15668455
    [No Abstract]   [Full Text] [Related]  

  • 15. The pragmatic use of apomorphine at the end of life.
    Dewhurst F; Lee M; Wood B
    Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apomorphine in dopaminergic therapy.
    Subramony JA
    Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apomorphine. A novel effect for an old compound.
    Scarselli M; Armogida M; Pardini C; Chiacchio S; Corsini GU
    Adv Neurol; 2001; 86():367-72. PubMed ID: 11553998
    [No Abstract]   [Full Text] [Related]  

  • 18. Apomorphine-subcutaneous--Bertek/Britannia.
    Drugs R D; 2004; 5(4):211-2. PubMed ID: 15230626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's Disease in the UK and Germany.
    Barnett G; Williams AC
    J Med Econ; 2015 Nov; 18(11):858-9. PubMed ID: 26121159
    [No Abstract]   [Full Text] [Related]  

  • 20. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.
    Garcia Ruiz PJ
    Mov Disord; 2006 May; 21(5):727-8. PubMed ID: 16547919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.